全文获取类型
收费全文 | 1041篇 |
免费 | 94篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 26篇 |
妇产科学 | 20篇 |
基础医学 | 142篇 |
口腔科学 | 11篇 |
临床医学 | 108篇 |
内科学 | 212篇 |
皮肤病学 | 39篇 |
神经病学 | 71篇 |
特种医学 | 17篇 |
外科学 | 158篇 |
综合类 | 4篇 |
一般理论 | 1篇 |
预防医学 | 167篇 |
眼科学 | 25篇 |
药学 | 50篇 |
肿瘤学 | 79篇 |
出版年
2024年 | 2篇 |
2023年 | 31篇 |
2022年 | 54篇 |
2021年 | 87篇 |
2020年 | 52篇 |
2019年 | 52篇 |
2018年 | 65篇 |
2017年 | 48篇 |
2016年 | 46篇 |
2015年 | 42篇 |
2014年 | 55篇 |
2013年 | 58篇 |
2012年 | 99篇 |
2011年 | 95篇 |
2010年 | 33篇 |
2009年 | 39篇 |
2008年 | 54篇 |
2007年 | 65篇 |
2006年 | 32篇 |
2005年 | 41篇 |
2004年 | 25篇 |
2003年 | 30篇 |
2002年 | 21篇 |
2001年 | 3篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1998年 | 2篇 |
1995年 | 1篇 |
1987年 | 1篇 |
1985年 | 1篇 |
排序方式: 共有1136条查询结果,搜索用时 15 毫秒
1.
Sarah E. Sheppard Laura Elizabeth Anderson Cathryn Sibbald Colleen Cotton Elizabeth Bhoj Marissa J. Perman Leslie Castelo‐Soccio 《Pediatric dermatology》2019,36(6):1007-1009
Epidermolysis bullosa simplex (EBS) is a skin fragility disorder resulting from mutations of structural proteins in the epidermis. We provide a brief report of long‐term survival and reproduction in a mother with EBS due to keratin 5 (KRT5) c.1429G > A (p.E477K) mutation, which causes a particularly severe form of the disease. 相似文献
2.
3.
4.
Mohan Srivarshini Cherukupalli Walcott-Sapp Sarah Lee Minna K. Srour Marissa K. Kim Sungjin Amersi Farin F. Giuliano Armando E. Chung Alice P. 《Annals of surgical oncology》2021,28(11):5907-5917
Annals of Surgical Oncology - Biomarker changes in patients with residual disease (RD) after neoadjuvant systemic therapy (NAT) have unclear consequences. This study examined the prevalence of... 相似文献
5.
Ashley D. Marumoto MD Srivarshini C. Mohan MD Stephanie A.K. Angarita MD Marissa K. Srour MD Vicky E. Norton Farnaz Dadmanesh MD Armando E. Giuliano MD 《The breast journal》2021,27(11):828-831
For women with breast cancer in whom multiple Oncotype DX® Recurrence Scores (RS) are obtained, RS concordance utilizing current NCCN recommendations has not been evaluated. Patients with two or more RS were identified. RS were stratified by NCCN guidelines and compared for concordance. Twenty-four patients were evaluated. RS concordance varied by tumor type: 100% in the same tumor, 91.7% in multiple ipsilateral tumors, 71.4% in contralateral tumors, and 66.7% in in-breast recurrent tumors. RS concordance for multiple assays in the same patient is not high enough to omit Oncotype DX® testing for each tumor. 相似文献
6.
Marissa Forbes Blair G Darney Shaalini Ramanadhan Mary Earp Lauren Waldner-James Leo Han 《Contraception》2021,103(4):276-281
ObjectiveWe sought to assess how women interpret the information they find online about the overall safety and risk of infertility associated with abortion and cesarean delivery (CD).MethodsWe conducted an exploratory, prospective study tracking the internet searches of 100 reproductive-aged individuals who identify as women. We directed participants to search for information about either (1) whether surgical abortion or CD is safe or (2) the risk of infertility following surgical abortion or CD. Our data collection had 3 phases: baseline survey, directed internet search, and a postsearch survey. We analyzed participants’ pre- and postsurvey responses using bivariate tests and analyzed within-subject changes. We evaluated the sites they visited based on expert ratings of site content based on trustworthiness and slant.ResultsWomen perceived abortion as safer and less likely to cause infertility after their web searches than before (70% perceived abortion in the United States as very/completely safe presearch vs 92% postsearch; p < 0.02). Women's perceptions about CD did not change. Participants sought information from web pages that experts largely deemed trustworthy and lacking in slant.ConclusionsWomen's perceptions about abortion safety and risk can be influenced by information they find online; perceptions about CD safety and risk may be less influenced by online information.ImplicationsDisseminating high quality, user-friendly abortion information on highly ranked and easily findable websites can help women find evidence-based information and influence knowledge about abortion. 相似文献
7.
8.
Violaine Planté-Bordeneuve Jared Gollob Sonalee Agarwal Marissa Betts Kyle Fahrbach 《Expert opinion on pharmacotherapy》2019,20(4):473-481
Background: Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a progressive, life-threatening disease. Until recently, tafamidis was the only approved pharmacotherapy. Patisiran significantly improved polyneuropathy and quality of life (QoL) in the phase III APOLLO trial. In the absence of direct comparisons, this analysis aimed to evaluate the comparative efficacy of tafamidis and patisiran in hATTR amyloidosis with polyneuropathy.Research design and methods: Randomized controlled trial evidence for tafamidis was identified by systematic literature review. Indirect treatment comparisons were performed using the standard pairwise Bucher method for endpoints used in both APOLLO and the tafamidis Fx-005 trial: change from baseline in Neuropathy Impairment Score-lower limbs (NIS-LL), Norfolk QoL-Diabetic Neuropathy questionnaire (QoL-DN), NIS-LL response, and mBMI vs. placebo. Inter-trial population differences were assessed by sensitivity analysis.Results: The base-case analysis (FAP Stage 1 APOLLO patients vs. intent-to-treat Fx-005 population) suggested patisiran had a greater treatment effect vs. tafamidis for all endpoints, with significant improvements in mean change in NIS-LL (–5.49) and QoL-DN (–13.10) from baseline to Month 18. Similar trends were observed in all sensitivity analyses.Conclusions: In the absence of direct comparisons, this analysis suggests patisiran has a greater treatment effect than tafamidis in patients with hATTR amyloidosis with polyneuropathy. 相似文献
9.
Kenan Gu Dennis Ruff Cassandra Key Marissa Thompson Shoshanna Jiang Taylor Sandison Shawn Flanagan 《CTS Clinical and Translational Science》2022,15(7):1592
Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of rezafungin after subcutaneous (s.c.) administration. The study design consisted of six sequential cohorts of eight subjects, except for the first cohort with four subjects. The subjects were randomized in a 3:1 ratio of rezafungin to placebo and were to receive a single dose of 1, 10, 30, 60, 100, or 200 mg. The most common adverse events (AEs) were increased alanine aminotransferase and sinus bradycardia (unsolicited) and erythema at the injection site (solicited). Unsolicited AEs were generally mild to moderate and not rezafungin‐related. Although the study was terminated after the 10 mg dose cohort due to concerns of potential increased severity of injection site reactions, no predetermined dose escalation halting criteria were met. Following the 10 mg single s.c. dose of rezafungin (n = 6), the geometric mean (GM) maximum concentration (C max) was 105.0 ng/ml and the median time to C max was 144 h. The GM area under the concentration‐time curve was 32,770 ng*h/ml. The median estimated terminal half‐life was 193 h. The GM apparent oral clearance was 0.255 L/h and the GM apparent volume of distribution was 68.5 L. This study demonstrates that a single s.c. dose of rezafungin in healthy adult subjects: (1) did not result in serious AEs, death, or withdrawal from the study due to an AE; and (2) produced a pharmacokinetic profile with long exposure period postadministration. In an effort to reduce the occurrence of injection site reactions, a re‐evaluation of the rezafungin s.c. formulation could be considered in the future. Study Highlights
- WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
- WHAT QUESTION DID THE STUDY ADDRESS?
- WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
- HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?